Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
Main finding · Composite major cardiovascular eventsResult — go to the resultHazard ratio 0.86 95% CI 0.77–0.97Authors' conclusion
In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF, compared with semaglutide, with a similar safety profile.
Study context
- Population
- Adults ≥18 years without diabetes initiating tirzepatide or semaglutide for obesity, November 2023–August 2024; excluded recent atherosclerotic events, prior heart failure (HF) or crossover to comparator35,336 matched pairs
- Exposure
- Tirzepatide vs semaglutide
- Outcome
- Major cardiovascular events: all-cause death, acute coronary syndrome, stroke or new-onset HF
- Follow-up
- 12 months
Methodological detailsactive-comparator, new-user, propensity-score matched (1:1), TriNetX global federated EHR database
- Active-comparator
- New-user
- Propensity-score matched (1:1)
- TriNetX global federated EHR database
Main finding
Composite major cardiovascular events
Hazard ratio
0.86
95% CI 0.77–0.97
P = 0.01
By group
Tirzepatidevs Semaglutide
HR 0.86 (95% CI 0.77–0.97); P = 0.01
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Tirzepatide | Semaglutide | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| New-onset HF (both reduced and preserved ejection fraction) | 1.04% | 1.29% | 0.79 (0.68–0.92) | P = 0.002 | |
| 0.512Hazard ratio (log scale) |
Mean, kg
| Outcome | Tirzepatide | Semaglutide | P value |
|---|---|---|---|
| Weight changeGreater weight loss with tirzepatide | −9.8 | −8.0 | P < 0.001 |
All-cause mortality, acute coronary syndrome, stroke
- No significant differences in all-cause mortality, acute coronary syndrome or stroke
Safety
- Adverse event rates were comparable, with no new safety signals
Original publication
Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults. Diabetes Obes Metab. Published 27 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →